本报讯 据耶路撒冷邮报消息，以损害人类健康而闻名的烟草有了新的用途。一个抗艾滋病生物制药实验正在欧洲进行，先进的分子农业技术将生产抗艾药物的地点从工厂转向了田间，从种植的烟草中获得抗艾药物将成为可能且成本低廉。
现在是实验的第一步，科学家将转基因烟草中生产的抗艾生物药物用于临床实验，在监管机构批准后，英国的11名健康妇女接受了单克隆抗体药物的实验，药物被制成阴道杀微生物制剂来阻止性交时艾滋病病毒的传播。目前，昂贵的抗体药物，如瑞士罗氏制药生产的抗癌药物赫塞汀和阿瓦斯汀都是在不锈钢容器中通过细胞培养的方法生产的。
来自伦敦大学圣乔治学院的项目协调人、分子生物学教授朱利安·马告诉媒体，已经有足够的实验证明，植物中生产的抗体的质量和工厂生产的是一样的。他说，希望这种低成本的技术最终能造福于贫穷国家，使他们也能掌握治疗癌症、类风湿性关节炎以及其他一些感染疾病的生物药物，大大降低这些药物的价格。
转基因制品在欧洲是个敏感的话题，大批民众反对转基因制品。但朱利安·马说，希望公众不要反对用转基因植物制药。这种植物将生长在被控制的温室中，况且烟草不是食物链的组成部分。
美国监管机构曾称，在决定是否给这种产品颁发许可前，他们需要更多数据。拜耳制药也在美国开展烟草抗癌药物研究，主要用于治疗血癌之一的非何杰金氏淋巴瘤。（冯志文）
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
| |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
Can be extracted from the tobacco material Kangai Yao
http://www.stdaily.com 2011 年 08 月 01 MVP: Science and Technology Daily Author: Feng Zhiwen
WASHINGTON According to the Jerusalem Post news, to the detriment of human health and well-known tobacco has a new purpose. An anti-AIDS experiments in Europe for bio-pharmaceutical, agricultural technology advanced molecular materials where the production Kangai Yao shifted from the factory farm, from growing tobacco to get Kangai Yao things will become possible and low cost.
It is the first step experiment, the scientists genetically modified tobacco in the biological production of anti-AIDS drugs for clinical trials, regulatory approval in the United Kingdom the 11 healthy women received the monoclonal antibody drug test, drugs were made into the vagina to kill microbial agents to prevent the spread of HIV during sexual intercourse. Currently, the expensive antibody drugs, such as Roche's cancer drug Herceptin and the production of Avastin are in stainless steel containers through the production of cell culture methods.
St. George's University of London School from the project coordinator, Professor Julian Ma of molecular biology, told the media that there is sufficient experimental evidence, the production of antibodies in plant quality and plant production is the same. He said he hoped that the ultimate low-cost technology can benefit poor countries, so that they can master the treatment of cancer, rheumatoid arthritis and other infectious diseases, biological drugs, significantly reduce the prices of these drugs.
Genetically modified products in Europe is a sensitive topic, a large number of people are opposed to genetically modified products. But Julian Ma said he hoped the public will not oppose the use of transgenic plants pharmaceuticals. This plant will grow in a controlled greenhouse Moreover, tobacco is not part of the food chain.
U.S. regulators have said that in deciding whether to license the product before this, they need more data. Bayer is also the United States to carry out tobacco anti-cancer drug research, primarily for the treatment of leukemia, one non-Hodgkin's lymphoma. (Feng Zhiwen)
